Scan evidence products
Evidence products prepared or updated with funding from COVID-END in Canada can be accessed below. These evidence products are shared through our twice-a-month Canadian spotlights and through many of our dissemination partners. If you want to receive an email containing hyperlinks to our Canadian (and global) spotlights twice a month, subscribe here.
| Title/question (if in progress) | Synthesis product type (product #) | Status | Date of last search (and publication) |
|---|---|---|---|
What is the long-term effectiveness of available COVID-19 vaccines for adults, including for variants of concern and over time frames beyond 112 days in those with a primary series and beyond 84 days in those with a primary series and an additional dose?
|
Living evidence synthesis (LES 10.15) |
Complete | 2023-02-22 (published 2023-02-24) |
|
What is the effectiveness of available COVID-19 vaccines for children and adolescents, including variants of concern? |
Living evidence synthesis (LES 8.21) | Complete | 2023-02-20 (published 2023-02-22) |
|
Effectiveness of ventilation for reducing transmission of COVID-19 and other respiratory infections in non-health care community-based settings |
Living evidence synthesis (LES 15.2) | Complete | 2023-02-03 (published 2023-03-09) |
|
Effectiveness of combinations of public health and social measures over time and across jurisdictions for reducing transmission of COVID-19 and other respiratory infections in non-healthcare community-based settings |
Living evidence synthesis (LES 20.2) | Complete | 2023-02-03 (published 2023-03-09) |
|
Effectiveness of interventions for promoting adherence to PHSMs for preventing COVID-19 and other respiratory infections in non-health care community-based settings |
Living evidence synthesis (LES 19.2) | Complete | 2023-02-03 (published 2023-03-09) |
|
Effectiveness of quarantine and isolation for reducing transmission of COVID-19 and other respiratory infections, as well as impacting other individual and social outcomes in non-health care community-based settings |
Living evidence synthesis (LES 13.2) | Complete | 2023-01-30 (published 2023-03-09) |
|
Effectiveness of masks for reducing transmission of COVID-19 and other respiratory infections in non-health care community-based settings |
Living evidence synthesis (LES 14.2) | Complete | 2023-01-30 (published 2023-03-09) |
|
Effectiveness of measures to reduce contacts for reducing transmission of COVID-19 and other respiratory infections in non-health care community-based settings |
Living evidence synthesis (LES 16.2a) | Complete | 2023-01-27 (published 2023-03-09) |
|
Effectiveness of physical distancing in reducing transmission of COVID-19 and other respiratory infections in non-health care community-based settings |
Living evidence synthesis (LES 16.2b) | Complete | 2023-01-27 (published 2023-03-09) |
|
Effectiveness of Cleaning and Disinfecting for reducing transmission of COVID-19 and other respiratory infections in non-health care community-based settings
|
Living evidence synthesis (LES 18.2) | Complete | 2023-01-03 (published 2023-03-09) |
| How were downstream health-promotion approaches that focus on individual behaviour change conceived of and used, and with what effectiveness, as part of COVID-19 pandemic preparedness and response? |
Rapid evidence profile (REP 46.2) | Complete | 2023-01-27 (2023-02-07) |
|
Effectiveness of Hand Hygiene and Respiratory Etiquette for reducing transmission of COVID-19 and other respiratory infections in non-health care community-based settings |
Living evidence synthesis (LES 17.1) | Complete | 2022-12-16 (published 2023-02-09) |
|
What are the characteristics of living-evidence syntheses currently available about public-health issues? |
Rapid evidence profile (REP #32) |
Complete | 2022-12-06 (published 2022-12-15) |
|
How antimicrobial use, infection prevention, and health system changes have impacted the emergence, transmission, and burden of antimicrobial resistance (AMR) during the COVID-19 pandemic |
Living evidence synthesis (LES 12.1) |
Complete | 2022-10-10 (published 2022-11-04) |
|
What is the socioeconomic impact of post COVID-19 condition (PCC)? |
Living evidence synthesis (LES 11.1) |
Complete | 7 October 2022 (published 2023-02-09) |
| Understanding the role of personal risk perceptions during the COVID-19 pandemic |
Rapid synthesis (RS 16) |
Complete | 2022-09-30 (2022-10-14) |
|
What is the effectiveness of available COVID-19 vaccines for adults, including for variants of concern and over time frames up to 120 days?
|
Living evidence synthesis (LES 6.41) |
Complete | 2022-09-14 (published 2022-09-15) |
|
Effectiveness of border closures/travel restrictions, screening and/ or quarantine to control the international spread of COVID-19 |
Rapid synthesis (RS 14) |
Complete | 2022-04-17 (published 2022-06-30) |
|
What is the incidence, associated risk factors, and clinical course of myocarditis and pericarditis following COVID-19 vaccination?
|
Living evidence synthesis (LES 9.3) | Complete | 2022-04-11 (published 2022-06-02) |
|
What is the impact of implementing (or removing) COVID-19 vaccine mandates on trust in institutions and in science, on psychological reactance, and/or on intention to get future doses/vaccines? |
Rapid synthesis (RS 13) |
Complete | 2022-03-25 (published 2022-04-01) |
|
What is the best-available synthesized evidence in relation to addressing key issues related to care for older adults during the COVID-19 pandemic? |
Response based on existing resources (Response 17) |
Complete | 2022-02-16 (2022-02-17) |
|
What is the best-available synthesized evidence in relation to addressing key health human resources issues? |
Response based on existing resources (Response 16) |
Complete | 2022-02-16 (2022-02-17) |
|
How has the COVID-19 pandemic affected the mental health of the general population? |
Response based on existing resources (Response 15) |
Complete | 2022-02-06 (2022-02-10) |
|
How has the COVID-19 pandemic (e.g., public-health measures, such as lockdowns) affected risk factors for chronic disease? |
Response based on existing resources (Response 14) |
Complete | 2022-02-06 (2022-02-10) |
|
What is the efficacy, immunogenicity, and safety of vaccines in the immunocompromised and those on dialysis? |
Rapid synthesis (RS 5.3) | Complete | 2022-01-17 (published 2022-05-30) |
| What is the filtration performance of KN95 masks compared to surgical and N95 masks, and how can their use be optimized in hospital settings? |
Rapid evidence profile (REP #28) |
Complete | 2022-01-10 (published 2022-01-12) |
| What measures and approaches can protect the most vulnerable in hospitals when outbreaks of Omicron in hospital are becoming more common? |
Rapid evidence profile (REP #27) |
Complete | 2022-01-06 (published 2022-01-10) |
|
What are the risk factors associated with severe COVID-19 outcomes in children 12 years and under? |
Rapid synthesis (RS 11.2) |
Complete | 2021-12-06 (2022-01-18) |
|
What is the best-available evidence about the management of long COVID symptoms and care models for long COVID patients? |
Living evidence synthesis (LES 7.2) |
Complete | 2021-12-04 (published 2021-12-15) |
|
What are the implications of SARS-CoV-2 variants for public-health measures and health-system arrangements?
|
Living evidence synthesis (LES 5.7) |
Complete | 2021-12-03 (published 2022-01-03) |
|
What are acceptable, effective approaches to organizing and delivering mental health and addictions services to adults virtually by registered health professionals? |
Response based on existing resources (Response 13) |
Complete | 2021-11-25 (2021-11-30) |
| Impact of rapid diagnostic testing on school closures |
Rapid synthesis (RS 12) |
Complete | 2021-11-06 (2022-01-07) |
| What evidence exists on the social and economic considerations for rapid diagnostic testing for COVID-19? |
Rapid synthesis (RS 2.2) |
Complete | 2021-11-03 (published 2021-11-09) |
What is known about supporting renewal in long-term care homes in light of the COVID-19 pandemic?
|
Living evidence profile (LEP 2.5) |
Complete | 2021-10-27 (published 2021-11-15) |
|
What is the effectiveness, immunogenicity and safety of COVID-19 vaccines in persons who have had a prior, confirmed COVID-19 infection? |
Rapid synthesis (RS 4.2) |
Complete | 2021-10-15 (published 2021-11-02) |
|
Do COVID-19 vaccines approved in Canada cause VITT (as a subset of TTS cases occurring within 60 days of vaccine administration) as an adverse event at a population level?
|
Rapid synthesis (RS 9) |
Complete | 2021-10-11 (2022-02-09) |
|
What is the best-available evidence about the effects of public-health measures in schools (K-12), as well as about supporting adherence to these measures? |
Response based on existing resources (Response 12) |
Complete | 2021-09-28 (2021-10-06) |
|
What is known about how schools (K-12) and post-secondary institutions (colleges and universities) adjust COVID-19 transmission-mitigation measures as infection rates change and vaccination rates increase? |
Living evidence profile (LEP 3.3) |
Complete | 2021-09-02 (published 2021-09-07) |
|
How can behavioural-science thinking help to support messaging to and broader supports for citizens, particularly those drawn from equity-seeking groups, to encourage them to be vaccinated
|
Living evidence synthesis (LES 4.5) |
Complete | 2021-08-31 (2021-09-01) |
|
What are the ways that AI technologies have been applied by various jurisdictions worldwide to mitigate, control, or prevent the COVID19 pandemic and its consequences? |
Rapid synthesis (RS 7) |
Complete | 2021-08-28 (2021-09-21) |
|
What screening methods, interventions, and system-level approaches can be used to address burnout in direct patient care providers due to COVID-19? |
Rapid synthesis (RS 6) |
Complete | 2021-08-27 (2021-09-30) |
| Can people who are vaccinated develop asymptomatic COVID-19 infection and transmit the virus to other individuals and, if so, how large is the risk compared to unvaccinated people and those infected with SARS-CoV-2 variants? | Living evidence synthesis (LES 1.3) |
Complete | 2021-08-23 (published 2021-09-24) |
| Has there been a change in the rate of pregnant persons admitted to the ICU or developing severe COVID-19 outcomes? |
Rapid synthesis (RS 1) |
Complete | 2021-08-20 (published 2021-09-07) |
|
What went well and what could have gone better in the COVID-19 response in other countries, as well as what will need to go well in future given any available foresight work being conducted? |
Living evidence profile (LEP 5.3) |
Complete | 2021-08-13 (published 2021-08-13) |
|
What went well and what could have gone better in the COVID-19 response in Canada, as well as what will need to go well in future given any available foresight work being conducted? |
Living evidence profile (LEP 4.4) |
Complete | 2021-08-13 (published 2021-08-13) |
What scientific evidence and international guidance exists on surveillance approaches to SARS-CoV-2 and its variants of concern in the context of moderate-to-high vaccination rates and low prevalence?
|
Rapid synthesis (RS 3) |
Complete | 2021-06-25 (published 2021-06-28) |
| How can behavioural-science thinking help to support messaging to and broader supports for healthcare workers to encourage them to: a) be vaccinated; and b) address vaccine hesitancy and enable vaccine uptake among their patients and citizens more generally, particularly those drawn from equity-seeking groups | Living evidence synthesis (LES 3.3) |
Complete | 2021-06-18 (published 2021-06-21) |
|
What is the best-available evidence about mental health and addictions impacts during the second and third wave of the COVID-19 pandemic and strategies to address such impacts for citizens and/or healthcare workers? |
Response based on existing resources (Response 11) |
Complete | 2021-06-02 (2021-06-02) |
What is known about anticipated COVID-19 vaccine roll-out elements?
|
Living evidence profile (LEP 1.7) |
Complete | 2021-05-28 |
|
What is the best-available evidence about the management of long COVID symptoms and care models for long COVID patients? |
Response based on existing resources (Response 10) |
Complete | 2021-05-07 (published 2021-05-11) |
|
How can vaccine acceptance and uptake be supported among equity seeking groups? |
Response based on existing resources (Response 5) |
Complete | 2021-05-04 |
|
What is known about the effects, communication, implementation and enforcement of nighttime curfews on COVID-19 infections? |
Response based on existing resources (Response 9) |
Complete | 2021-04-14 |
|
What is the best-available evidence about the use of colchicine and ivermectin for COVID-19? |
Response based on existing resources (Response 8) |
Complete | 2021-04-09 |
|
What is the best-available evidence about the impact of COVID-19 on developing coagulopathies? |
Response based on existing resources (Response 7) |
Complete | 2021-04-08 |
|
What is known about the development, implementation, and funding of long COVID-19 clinics across jurisdictions? |
Response based on existing resources (Response 6) |
Complete | 2021-04-06 |
|
What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? |
Response based on existing resources (Response 4) |
Complete | 2021-03-26 |
| When and in what order can COVID-19-related public-health measures be lifted (or stringency be reduced) as vaccination rates and seasonal temperatures increase? | Rapid evidence profile (REP #26) |
Complete | 2021-03-17 (published 2021-03-18) |
| What are the transmission characteristics of SARS-CoV-2 variants of concern? | Rapid synthesis (RS 15) |
Complete | 2021-03-01 (published 2021-03-17) |
| What factors affect health workers’ attitudes toward vaccination uptake and what strategies have been successful in increasing vaccination among health workers? | Response based on existing resources (Response 3) |
Complete | Last updated 2021-02-04 |
| Can people who are vaccinated develop asymptomatic COVID-19 infection and transmit the virus to other individuals and, if so, how large is the risk compared to unvaccinated people? | Response based on existing resources (Response 2) |
Complete | Last updated 2021-02-04 |
| What do we know from both research and jurisdictional scans about prioritizing vaccination of asymptomatic residents in a long-term care home with an outbreak? | Rapid evidence profile (REP #25) |
Complete | 2021-01-19 (published 2021-01-20) |
| How can we best leverage existing resources to provide evidence-based advice on COVID-19 therapeutics and issue guidance statements to inform decision makers and healthcare professionals on the use of pharmaceuticals for the treatment or chemoprophylaxis of COVID-19? | Response based on existing resources (Response 1) |
Complete | Last updated 2020-12-20 |
Our evidence products can take many forms:
- response based on existing resources
- one-off rapid evidence profile or rapid synthesis
- living evidence profile or living evidence synthesis that is updated regularly.
Our evidence profiles and evidence syntheses vary in:
- the effort that goes into them, which we measure in the number of hours or days that a very large team of highly experienced staff devote exclusively to the task (e.g., four hours to three days for evidence profiles and for updates to living evidence profiles; five to ten days for rapid syntheses and for updates to living evidence syntheses)
- the type of best evidence they include and whether they also include a jurisdictional scan.
Below we provide examples of how these evidence products can vary.
| Product type | Best evidence | Jurisdictional scan |
|---|---|---|
| Rapid evidence profile (four hours) | Profile of existing evidence syntheses |
1-2 provinces and 1-2 countries |
| Rapid evidence profile (1 day) |
Same but with more decision-relevant information extracted and quality rating of evidence syntheses |
3-4 provinces and 3-4 countries |
| Rapid evidence profile (2 days) |
Same but with even more decision-relevant information extracted |
5-6 provinces and 5-6 countries |
| Rapid evidence profile (3 days) |
Same plus profile of singles studies |
All Canadian jurisdictions and up to 10 countries |
| Rapid review – Scoping (5-10 days) |
Inventory of syntheses and single studies |
No |
| Rapid review – Overview (5-10 days) |
Overview of syntheses with quality ratings |
No |
| Rapid review – Synthesis (5-10 days) |
Synthesis of single studies with risk-of-bias assessment |
No |